Epilepsy

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 27, 2026.

Purple Day, observed each March 26, highlights the global impact of epilepsy while encouraging awareness, education, and open dialogue to reduce stigma and improve care for millions worldwide.

For Purple Day, M. Scott Perry, MD, a leader within the epilepsy community, shared thoughts and perspectives on the persistent gaps in epilepsy awareness, the hope for precision therapies, and the need for holistic care.

Adult epileptologist Danielle Becker, MD, MS, FAES, emphasized the need for improved education and structured, lifespan-based care to better address sex-specific risks in women with epilepsy.

The POLARIS program includes 3 ongoing phase 1/2 clinical trials investigating the efficacy and safety of investigational gene therapy EXT101 in patients with SCN1A postive Dravet syndrome.

In honor of Purple Day®, held on March 26, 2026, Mary Anne Meskis, chief executive officer of the Dravet Syndrome Foundation, highlighted ongoing efforts and future steps to raise awareness for rare epileptic disorders.

A post hoc analysis of the AMPA observational study found that adjunctive perampanel did not worsen daytime sleepiness over 12 months in patients with focal epilepsy while maintaining substantial seizure reduction.

Phase 3 data show azetukalner cuts monthly focal seizures in refractory epilepsy, offering a novel KV7 option ahead of 2026 FDA filing.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Neurologists Esther Bui, MD, and Angela O'Neal, MD, talked about the INSIGHT network, a collaborative global initiative designed to advance medical education in women’s neurology.

Praxis files FDA NDAs for ulixacaltamide and relutrigine, highlighting phase 3 tremor gains and major seizure cuts in rare DEEs.

Here's some of what is coming soon to NeurologyLive® this week.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Here's some of what is coming soon to NeurologyLive® this week.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents for International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.

The director of the Center for Clinical Ethics at Yale New Haven Health discussed the rationale behind the newly published AAN guidelines on functional seizures, outlining diagnostic priorities, evidence-based treatment recommendations, and key gaps.

In honor of National Women Physician’s Day, the NeurologyLive® team highlighted recent studies on women transforming neurologic care and advancing women’s health.

Epilepsy titan Page B. Pennell, MD, FAES, FAAN, FANA, outlined key hormonal, reproductive, and treatment-related factors that influence epilepsy management and outcomes for women in different life stages.

The director of the Center for Clinical Ethics at Yale New Haven Health outlined how the AAN guidelines address the role of pharmacologic therapies in functional seizures, including what evidence exists and when medications should or should not be used. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.